Interactive Features

Test Your Knowledge

Quiz: Is Cervicovaginal Microbiota Type a Risk Factor for Ovarian Cancer?

12/21/2020

True or false: Type O cervicovaginal microbiota has been linked to higher risk for ovarian cancer.

True or false: Type O...

12/21/2020

Oncology

Test Your Knowledge

Quiz: Does Nivolumab Improve OS Vs Gem/PLD in Platinum-Resistant Ovarian Cancer?

12/11/2020

True or false: Nivolumab improved overall survival versus gemcitabine/pegylated liposomal doxorubicin in platinum-resistant ovarian cancer.

True or false: Nivolumab...

12/11/2020

Oncology

Test Your Knowledge

Quiz: Is Significant Clinical Benefit Derived From Maintenance Olaparib for BRCA-Mutated Ovarian Cancer?

11/10/2020

True or false: Long-term olaparib maintenance significantly extended PFS over placebo in BRCA-mutated ovarian cancer.

True or false: Long-term...

11/10/2020

Oncology

Test Your Knowledge

Quiz: Which Therapy Extended PFS for Ovarian Cancer in the ARIEL3 Study?

10/08/2020

According to the ARIEL3 study, _______ extended PFS for ovarian cancer despite toxicities?

According to the ARIEL3 study,...

10/08/2020

Oncology

Test Your Knowledge

Quiz: Could Cancer Cells in Endometrial Cysts Improve Ovarian Cancer Detection?

09/01/2020

True or False: Endometriosis-associated ovarian cancer often occurs within 36 months of follow-up for endometrial cysts, leading experts to suggest that cancer cells may already be present in endometrial cysts.

True or False:...

09/01/2020

Oncology

Test Your Knowledge

Quiz: Which Combination Benefits Patients with Mesothelin-Expressing Solid Tumors?

08/06/2020

Which combination yielded manageable safety and encouraging antitumor activity in patients with mesothelin-expressing solid tumors?

Which combination yielded...

08/06/2020

Oncology

Test Your Knowledge

Quiz: Long-Term Maintenance Olaparib for BRCA-Mutated, Relapsed Ovarian Cancer?

06/25/2020

True or false: Maintenance olaparib did not provide a significant OS improvement in a phase 3 study of patients with platinum-sensitive, BRCA-mutated, relapsed ovarian cancer.

True or false: Maintenance...

06/25/2020

Oncology

Test Your Knowledge

Quiz: Does Maintenance Pazopanib Improve OS for Advanced Ovarian Cancer?

05/22/2020

True or false: Maintenance pazopanib improved overall survival in advanced ovarian cancer in a phase 3 clinical trial.

True or false: Maintenance...

05/22/2020

Oncology

Test Your Knowledge

Quiz: Efficacy of Gemcitabine–Pazopanib Combo in Ovarian Cancer

04/14/2020

True or False: Adding pazopanib to gemcitabine has been shown to enhance antitumor activity in patients with ovarian cancer.

True or False: Adding pazopanib...

04/14/2020

Oncology

Test Your Knowledge

Quiz: What Yields Better Response Than Chemo in Relapsed Ovarian Cancer?

04/09/2020

Among pretreated patients with relapsed ovarian cancer, what significantly improved PFS vs nonplatinum chemo?

Among pretreated patients with...

04/09/2020

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology